NASDAQ:KLDOKaleido Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kaleido Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.59 +0.01 (+0.15 %) (As of 08/6/2020 04:00 PM ET) Add Compare Share Today's Range$6.50Now: $6.59▼$6.7550-Day Range$5.97MA: $6.87▼$7.8052-Week Range$2.82Now: $6.59▼$10.36Volume86,009 shsAverage Volume155,906 shsMarket Capitalization$200.95 millionP/E RatioN/ADividend YieldN/ABeta-0.19 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingKaleido Biosciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Kaleido Biosciences has a potential upside of 6.2% from its current price of $6.59.Amount of Analyst CoverageKaleido Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesKaleido Biosciences has received 37 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKaleido Biosciences has received 56 “underperform” votes. (Add your “underperform” vote.)Community SentimentKaleido Biosciences has received 60.22% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote “Outperform” if you believe KLDO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKaleido Biosciences does not currently pay a dividend.Dividend GrowthKaleido Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kaleido Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,249,998.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of Kaleido Biosciences is held by insiders.Percentage Held by Institutions80.11% of the stock of Kaleido Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kaleido Biosciences are expected to decrease in the coming year, from ($2.13) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kaleido Biosciences is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kaleido Biosciences is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 1.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KLDO Previous Symbol CUSIPN/A CIKN/A WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees91 Outstanding Shares30,493,000Market Cap$200.95 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $6.59 +0.01 (+0.15 %) (As of 08/6/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive KLDO News and Ratings via Email Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter. Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions How has Kaleido Biosciences' stock been impacted by COVID-19 (Coronavirus)? Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KLDO shares have increased by 19.0% and is now trading at $6.59. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Kaleido Biosciences? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kaleido Biosciences. When is Kaleido Biosciences' next earnings date? Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Kaleido Biosciences. How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences Inc (NASDAQ:KLDO) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.59) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.59). View Kaleido Biosciences' earnings history. What price target have analysts set for KLDO? 3 brokerages have issued 1-year target prices for Kaleido Biosciences' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Kaleido Biosciences' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View analysts' price targets for Kaleido Biosciences. Has Kaleido Biosciences been receiving favorable news coverage? Media stories about KLDO stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kaleido Biosciences earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Kaleido Biosciences. Are investors shorting Kaleido Biosciences? Kaleido Biosciences saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 2,140,000 shares, a drop of 5.7% from the July 15th total of 2,270,000 shares. Based on an average daily volume of 166,900 shares, the days-to-cover ratio is currently 12.8 days. Currently, 19.7% of the company's stock are sold short. View Kaleido Biosciences' Current Options Chain. Who are some of Kaleido Biosciences' key competitors? Some companies that are related to Kaleido Biosciences include Endo International (ENDP), Kura Oncology (KURA), Poseida Therapeutics (PSTX), Cara Therapeutics (CARA), Fulgent Genetics (FLGT), PureTech Health (PRTC), Nkarta (ANNX), Opthea (OPT), Cryolife (CRY), OraSure Technologies (OSUR), Codexis (CDXS), Hanger (HNGR), Morphic (MORF), Nkarta (NKTX) and Atara Biotherapeutics (ATRA). View all competitors. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Tcr2 Therapeutics (TCRR), Harpoon Therapeutics (HARP), QUALCOMM (QCOM) and Exxon Mobil (XOM). Who are Kaleido Biosciences' key executives? Kaleido Biosciences' management team includes the following people: Mr. Michael W. Bonney, Exec. Chair (Age 62, Pay $397.5k)Ms. Alison Lawton, CEO, Pres & Director (Age 59, Pay $1.04M)Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 39, Pay $35k)Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 41, Pay $464.81k)Dr. Katharine Knobil M.D., Chief Medical Officer and Head of R&D (Age 55, Pay $868.03k) When did Kaleido Biosciences IPO? (KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Kaleido Biosciences' stock symbol? Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO." Who are Kaleido Biosciences' major shareholders? Kaleido Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bessemer Group Inc. (0.12%) and Bainco International Investors (0.05%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship and Ventures Fund V LP Flagship. View institutional ownership trends for Kaleido Biosciences. Which major investors are selling Kaleido Biosciences stock? KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors. View insider buying and selling activity for Kaleido Biosciences. Which major investors are buying Kaleido Biosciences stock? KLDO stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship, and Ventures Fund V LP Flagship. View insider buying and selling activity for Kaleido Biosciences. How do I buy shares of Kaleido Biosciences? Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kaleido Biosciences' stock price today? One share of KLDO stock can currently be purchased for approximately $6.59. How big of a company is Kaleido Biosciences? Kaleido Biosciences has a market capitalization of $200.95 million. Kaleido Biosciences employs 91 workers across the globe. This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
